Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative dostarlimab versus standard of care for resectable dMMR/MSI-H colon cancer
2023-503265-27-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial in colon adenocarcinoma and colorectal cancer (CRC) comparing Perioperative dostarlimab monotherapy with Standard of care (2 arms). Primary endpoint: Event-free survival. Planned start Nov 2023; status: authorised.
02
Drugs
dostarlimab
03
Conditions
colon adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-503265-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503265-27-00.